Bayhill Therapeutics enters exclusive, worldwide collaboration with Genentech for BHT-3021 in Type 1 diabetes

News | 06. 10. 2009

Bayhill Therapeutics

 
SAN MATEO, Calif.–(BUSINESS WIRE)–Bayhill Therapeutics Inc. announced today that it has entered into an exclusive worldwide license agreement for the development and potential commercialization of BHT-3021 with Genentech, Inc. a wholly-owned member of the Roche Group. BHT-3021 is Bayhill’s DNA based antigen specific immunotherapy currently in a phase I/II clinical trial in patients with type 1 diabetes (T1D).